Trulicity (dulaglutide, Eli Lilly) and Ozempic (semaglutide, Novo Nordisk) are once-weekly GLP-1 receptor agonists FDA-approved for type 2 diabetes. This head-to-head covers mechanism, SUSTAIN 7 data, boxed-warning safety, April 2026 list pricing, and the FTO, MC4R variants that shape every GLP-1 response.

Rybelsus is oral semaglutide, and this independent explainer covers what the tablet is, the GLP-1 receptor biology it uses, what the PIONEER program measured, how its FDA diabetes label frames weight change, and the inherited variants that shape any GLP-1 pathway decision.

A mechanism-first look at tirzepatide as of April 2026: how native GLP-1 becomes a long-acting receptor-agonist drug, why tirzepatide's dual GIP/GLP-1 action stands out from single agonists, which compounds are FDA-approved, and the FTO, and MC4R variants that shape the underlying pathway.

Rybelsus and Ozempic are two delivery formats of the same active ingredient, semaglutide. This comparison covers the oral tablet versus the weekly injection across pharmacology, PIONEER and SUSTAIN trial evidence, FDA indications, tolerability, list price, and the shared genetic terrain.

Victoza and Ozempic are both Novo Nordisk GLP-1 agonists, but they differ in molecule, dosing rhythm, and price. This independent review compares liraglutide and semaglutide on design, approved indications, trial evidence, safety, and list price, then the genetics that apply beneath either prescription.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

GLP-1 and GLP-2 are distinct gut peptides from the same proglucagon precursor. GLP-1 receptor agonists treat type 2 diabetes and obesity. GLP-2 (teduglutide / Gattex) treats short bowel syndrome. This article explains the biology, the drugs, and the GLP-1 pathway genetics.

A GLP-1 receptor agonist is widely searched in a weight-loss context. This guide covers how it works at the pathway level, what the published trials show, the FDA labeling context as of April 2026, the limitations worth knowing, and the genetics upstream of every decision.

GLP-1 receptor agonism is the biological action of switching on the GLP-1 receptor. This guide follows the mechanism step by step, from the native hormone through engineered agonists, lists the FDA-approved compounds as of April 2026, and explains the genetics upstream.

GLP-1 drugs share one pathway but differ in molecule and indication. This PlexusDx guide explains what native GLP-1 is, how receptor agonists work, which compounds are FDA-approved as of April 2026, and the genetic variables that sit upstream of the entire class.

GLP-1 medications mimic an incretin hormone your gut releases after eating. This explainer covers what native GLP-1 is, how receptor-agonist drugs extend its short half-life, which compounds are FDA-approved as of April 2026, and the genetic variables that sit upstream of the class.

GLP-1 receptor agonists are widely searched for weight loss as a category. This guide covers the shared mechanism, what the major trial programs reported, the FDA labeling context as of April 2026, the limitations worth knowing, and the genetics upstream of every decision.

A mechanism-first guide that reads the term one word at a time: what a GLP-1 receptor agonist actually is, what the receptor does when it fires, the DPP-4 engineering problem the drug solves, and the inherited variation in the pathway that sits above it all.

This guide focuses on which GLP-1 receptor agonist medicines are FDA-approved as of April 2026, walks through how they work, notes the investigational compounds still in development, and explains the pathway-level genetic variables that sit upstream of any GLP-1 decision you and a provider might discuss.

The plural points to the whole family. This overview maps GLP-1 receptor agonists as a set: the mechanism uniting them, how members diverge in half-life and receptor targeting, the formats they come in, and the single genetic backdrop that applies to all of them at once.

GLP-1 "shots" are injectable receptor agonists used in weight management. This PlexusDx explainer covers how the injection changes appetite, what the trials measured, who should avoid it, and how genes like FTO shape the metabolic terrain underneath any decision.

This article starts with the hormone itself: where glucagon-like peptide-1 comes from, what it does in the minutes after a meal, why it fades so quickly, how medicine reproduced its signal into lasting drugs, and the inherited variation that shapes GLP-1 biology in every body.

This explainer starts with the word agonist, unpacking what it means to switch on the GLP-1 receptor, how the drug versions outlast the natural hormone, where single, dual, and triple agonism differ across the class, and how your inherited genes frame the entire pathway.

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

"GLP-1 inhibitors" is one of the most common misnomers in metabolic medicine. This article explains what GLP-1 actually is, why the medications are agonists rather than inhibitors, how DPP-4 inhibitors differ, which compounds are approved, and the genetics of the pathway.

GLP-1 receptor agonists are widely discussed for weight loss. This guide explains how the pathway works, what the published trial programs show, the FDA labeling context as of April 2026, the limitations and contraindications worth knowing, and the genetic variables that sit upstream of every GLP-1 decision.

"GLP-1 drugs for weight loss" searches want the clinical record. This article covers the weight-relevant mechanism, the trial-reported reduction range, the FDA-approved weight-management products, the class safety limits, and the inherited variables that PlexusDx maps behind each individual person's outcome.

This page focuses on the injectable side of Wegovy, why the drug is delivered by injection, how the once-weekly format supports its GLP-1 mechanism, what the STEP program reported, and who the injection is not right for, finishing with genetic context.

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

A plain-language roster of GLP-1 medications: what the drug class does inside the body, which agents carry FDA approval and when, how the injections differ from the single oral tablet, what compounded means, and where your inherited genes fit into the whole picture.

GLP-1 receptor agonists became famous for weight loss, but the effect is downstream biology, not a shortcut. This PlexusDx explainer traces the appetite mechanism, reviews what the weight trials actually measured, notes where results reach their limits, and shows how genes like FTO shape the metabolic terrain first.

Wegovy weight loss is a phrase carrying a lot of expectation. This page grounds it in the receptor-level mechanism, the STEP trial findings reported in the literature, the FDA-approved indication, and the contraindications worth knowing, followed by honest genetic context.

This overview walks through how semaglutide is weighed clinically for weight loss, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approved indications, contraindications, and the inherited variables that shape any GLP-1 decision. Facts stay tied to published labeling and literature, not guarantees.

Trulicity is a long-acting GLP-1 receptor agonist that many people search in a weight-loss context. This guide walks through its receptor-level mechanism, the AWARD and REWIND trial evidence, its FDA-approved indications, the boxed warning, and the genetic variants that sit upstream of every GLP-1 conversation.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.